GLP-1 Medications and Heart Health: What the Cardiovascular Research Shows for Seniors

Most people think of GLP-1 medications as weight loss drugs. But for seniors — especially those with heart disease, high blood pressure, or a history of cardiovascular events — the most important benefit may have nothing to do with the number on the scale. In 2023, a landmark clinical trial called SELECT proved that semaglutide (the active ingredient in Wegovy) reduced the risk of heart attacks, strokes, and cardiovascular death by 20 percent in adults with obesity and established heart disease. That finding changed the way cardiologists think about these medications and is one of the key reasons Medicare now covers them through the Bridge program.

The SELECT trial: what it proved

The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a massive, randomized, double-blind study that enrolled over 17,600 adults aged 45 and older. All participants had established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) and a BMI of 27 or higher, but none had diabetes.

The results, published in the New England Journal of Medicine in November 2023, showed that semaglutide 2.4 mg (the Wegovy dose) reduced the combined risk of cardiovascular death, non-fatal heart attack, and non-fatal stroke by 20 percent compared to placebo over a median follow-up of approximately 40 months.

This was not a small or ambiguous result. It was a statistically significant, clinically meaningful reduction in the most serious cardiovascular events — the kind of events that kill or permanently disable people. Based on these results, the FDA approved a new indication for Wegovy: reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight.

Why does a weight loss medication protect the heart?

The cardiovascular benefits of GLP-1 medications appear to go beyond simple weight loss. While losing weight does reduce strain on the heart, the SELECT trial found that the heart benefits were significant even after accounting for the amount of weight lost. This suggests that GLP-1 medications have direct cardiovascular effects, including:

• Reduced inflammation — chronic low-grade inflammation is a major driver of atherosclerosis (plaque buildup in arteries). GLP-1 medications appear to reduce inflammatory markers like C-reactive protein (CRP), which was significantly lowered in the SELECT trial.
• Improved blood pressure — participants in GLP-1 trials consistently showed modest but meaningful reductions in systolic blood pressure.
• Better lipid profiles — improvements in cholesterol and triglyceride levels were observed across multiple GLP-1 trials.
• Improved insulin sensitivity — even in non-diabetic patients, better glucose metabolism reduces cardiovascular risk.
• Reduced arterial stiffness — early research suggests GLP-1 medications may improve the flexibility of blood vessel walls, which hardens with age and contributes to hypertension and heart failure.

What about tirzepatide (Zepbound) and heart health?

As of mid-2026, tirzepatide does not yet have completed cardiovascular outcome trial data comparable to SELECT. The SURPASS-CVOT trial is currently underway and is studying cardiovascular outcomes specifically in patients taking tirzepatide, but final results have not been published.

This does not mean Zepbound is unsafe for the heart — preliminary data and secondary analyses from the SURMOUNT trials suggest favorable cardiovascular trends. But it does mean that if you have established heart disease and your doctor is choosing between Wegovy and Zepbound, the proven cardiovascular evidence currently favors Wegovy.

What the SELECT trial means for Medicare seniors

Heart disease is the leading cause of death in adults over 65. According to the American Heart Association, more than 80 percent of cardiovascular disease deaths occur in people aged 65 and older. For this population, a medication that reduces heart attack and stroke risk by 20 percent — while also helping with weight loss, blood sugar, and blood pressure — represents a significant clinical advance.

The SELECT trial is also one of the key reasons the Medicare GLP-1 Bridge program was created. The cardiovascular evidence made it much harder for policymakers to argue that these medications are cosmetic or elective — they are, in many cases, cardiovascular interventions that happen to also cause weight loss.

How GLP-1 medications fit into an existing heart treatment plan

GLP-1 medications do not replace existing cardiovascular medications. If you take statins, blood pressure medications, blood thinners, or other cardiac drugs, you will continue taking those alongside your GLP-1. The medications work through different mechanisms and are complementary.

However, as you lose weight and your blood pressure and blood sugar improve, your doctor may need to adjust dosages of other medications. For example, if your blood pressure drops significantly from the combined effect of weight loss and the GLP-1, your blood pressure medication dose might need to be reduced to avoid hypotension (dangerously low blood pressure). Similarly, diabetic patients may need insulin or sulfonylurea dose reductions to prevent hypoglycemia.

This is why regular follow-up appointments are essential during GLP-1 treatment — especially for seniors managing multiple cardiovascular medications. Your doctor needs to monitor and adjust your full medication regimen as your body changes.

Blood pressure improvements on GLP-1 medications

Across multiple clinical trials, GLP-1 medications have consistently shown modest reductions in systolic blood pressure — typically 3 to 6 mmHg on average, with some patients seeing larger drops. While this may sound small, population-level research has shown that even a 5 mmHg reduction in systolic blood pressure reduces the risk of stroke by approximately 14 percent and the risk of heart disease by approximately 9 percent.

For seniors who already take blood pressure medication and are still above target, the additional reduction from a GLP-1 can be clinically meaningful. For those whose blood pressure is already well-controlled, it means closer monitoring to prevent it from dropping too low.

Should you ask your cardiologist about a GLP-1?

If you are a Medicare beneficiary with obesity (BMI 27 or higher) and any of the following, a conversation with your cardiologist about GLP-1 medication is worth having:

• Prior heart attack or stroke.
• Coronary artery disease or peripheral artery disease.
• Heart failure with preserved ejection fraction (HFpEF) — early research suggests potential benefits here as well.
• Uncontrolled hypertension despite medication.
• Elevated inflammatory markers (high CRP).
• Multiple cardiovascular risk factors — diabetes, high cholesterol, smoking history, family history.

The SELECT trial demonstrated that the cardiovascular benefit applies specifically to patients who already have established heart disease. For seniors with obesity but no cardiovascular disease, the primary benefit remains weight loss and metabolic improvement rather than proven cardiovascular risk reduction.

Tracking your blood pressure, weight, meals, and symptoms daily on CairnSpace gives your cardiologist a complete picture of how the medication is affecting your cardiovascular health over time. Bring a summary of your tracking data to each follow-up appointment — the trends are often more informative than any single measurement taken in the office.

Related Articles

• Wegovy vs Zepbound: Which GLP-1 Is Right for Seniors on Medicare?
• GLP-1 Medications and Your Other Prescriptions: What Seniors Need to Know
• Does Medicare Cover GLP-1 Weight Loss Medications in 2026?
• How Old Is Too Old for a GLP-1? What Doctors and Research Actually Say

Sources

• Lincoff AM et al. — Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial), New England Journal of Medicine (2023)
• FDA — approval of Wegovy supplemental indication for cardiovascular risk reduction (March 2024)
• American Heart Association — Heart Disease and Stroke Statistics, 2024 Update
• Ettehad D et al. — Blood Pressure Lowering for Prevention of Cardiovascular Disease and Death, The Lancet (2016)
• FDA prescribing information — Wegovy (semaglutide) cardiovascular indication and trial data